Clascoterone
A topical androgen receptor inhibitor that blocks the effects of dihydrotestosterone and other androgens in sebaceous glands and hair follicles, reducing sebum production and inflammation in acne-prone skin. It is applied directly to affected areas and has minimal systemic absorption, reducing the risk of systemic anti-androgenic effects. It is approved for the topical treatment of acne vulgaris in patients aged 12 and older.
Masse moléculaire
402,5000 g/mol
LogP
3,90
TPSA
80,70 Ų
Règle des 5 de Lipinski
Conforme
Mécanisme d'action
Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.
Structure 2D
Cite this structure
Embed this structure
SMILES
CCC(=O)O[C@]1(C(=O)CO)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C
InChI
InChI=1S/C24H34O5/c1-4-21(28)29-24(20(27)14-25)12-9-19-17-6-5-15-13-16(26)7-10-22(15,2)18(17)8-11-23(19,24)3/h13,17-19,25H,4-12,14H2,1-3H3/t17-,18+,19+,22+,23+,24+/m1/s1
Molecular Formula
C24H34O5
HBD / HBA
1 / 5
Liaisons Rotatives
5
Atomes Lourds
29
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Foire aux questions
A topical androgen receptor inhibitor that blocks the effects of dihydrotestosterone and other androgens in sebaceous glands and hair follicles, reducing sebum production and inflammation in acne-prone skin. It is applied directly to affected areas and has minimal systemic absorption, reducing the risk of systemic anti-androgenic effects. It is approved for the topical treatment of acne vulgaris in patients aged 12 and older.
Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.
Yes, Clascoterone is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3590187. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 11750009. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="clascoterone"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/clascoterone/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/clascoterone/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/clascoterone/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="clascoterone"></drugfyi-drug>